Table 5.

Comparison of response between patients with false-negative to true-positive and true-negative SLNs after NAST

	True-pos and true-neg (%)	False-neg (%)	P
No. of patients	139	13
Pathologic response, tumoral (ypT)
Sataloff T-A	49 (35.3)	1 (7.7)
Sataloff T-B	39 (28.1)	7 (53.8)
Sataloff T-C	43 (30.9)	3 (23.1)
Sataloff T-D	8 (5.8)	2 (15.4)	0.044
Pathological response, nodal (ypN)
Sataloff N-A	38 (27.3)	0 (0.0)
Sataloff N-B	22 (15.8)	0 (0.0)
Sataloff N–C	39 (28.1)	5 (28.5)
Sataloff N-D	40 (28.8)	8 (61.5)	0.010

Sataloff T-A: Total or near total therapeutic effect; Sataloff T-B: >50% therapeutic effect but less than total or near total; Sataloff T-C: <50% therapeutic effect, but effect evident; Sataloff T-D: No therapeutic effect

Sataloff N-A: Evidence of therapeutic effect, no metastatic disease; Sataloff N-B: No nodal metastasis or therapeutic effect; Sataloff N-C: Evidence of therapeutic effect but nodal metastasis still present; Sataloff N-D: Viable metastatic disease, no therapeutic effect

SLN sentinel lymph node, NAST neoadjuvant systemic therapy